29 April 2025 - Report will be subject of New England CEPAC meeting in November 2025; draft scoping document open to public comment until 19 May 2025.

The ICER announced today that it will assess the comparative clinical effectiveness and value of tirzepatide (Zepbound, Eli Lilly) and semaglutide (Wegovy, Novo Nordisk) for the treatment of obesity. ICER will also assess how these treatments affect additional obesity-related outcomes.

Read ICER Announcement